Investors put $93mm into Paratek as part of merger with Transcept

As part of its reverse merger with public neuroscience firm Transcept Pharmaceuticals Inc., infectious disease-focused Paratek Pharmaceuticals Inc. will receive $93mm from its current stockholders Omega Funds, HBM Healthcare Investments, and Aisling Capital; Transcept shareholders InterWest Ventures and Roumell Asset Management; and new backers The Baupost Group, Abingworth, and other institutional investors. Post-acquisition, Paratek will focus on lead compound omadacycline, a Phase III-ready oral and intravenous antibiotic.